ArticleKorean journal of ophthalmology : KJO2026
Surgical Outcomes of A-Stream Shunt Implantation in Neovascular Glaucoma: A Single-Center Retrospective Cohort Study.
Article in Korean journal of ophthalmology : KJO, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate 6-month surgical outcomes of A-stream shunt implantation in eyes with neovascular glaucoma (NVG) and to describe postoperative ripcord management patterns.
methodsThis retrospective, single-center cohort study included consecutive NVG eyes that underwent A-stream shunt implantation between August 2024 and April 2025 with available follow-up through 6 months. Intraocular pressure (IOP) and the number of glaucoma medications were assessed at postoperative day 1, week 1, weeks 2-3, and months 1, 2, 3, and 6. Complete success was defined as IOP 6 to 18 mmHg with ≥20% reduction from preoperative decision IOP, without glaucoma medications or additional glaucoma surgery. Qualified success was defined using the same IOP and reduction criteria with or without medications, and without additional glaucoma surgery. Ripcord removal timing and postoperative interventions were recorded.
resultsThirty-five eyes were included. Mean preoperative IOP was 37.0 ± 13.2 mmHg on 2.6 ± 1.2 medications. Mean IOP decreased to 10.1 ± 6.9 mmHg on postoperative day 1 and remained in the mid-teens through 6 months (15.7 ± 6.3 mmHg). Medication burden was markedly reduced postoperatively and remained low at 6 months (0.7 ± 0.9). Ripcord removal was performed in 28 eyes (80.0%); mean time to removal was 6.6 ± 4.7 weeks, and 14 eyes (40.0%) underwent removal within 4 weeks. Mean IOP at ripcord removal was 21.2 ± 5.4 mmHg. At 6 months, complete and qualified success rates were 57.1% and 85.7%, respectively. Bleb needling and 5-fluorouracil injections were performed in 14.3% and 25.7% of eyes, respectively; one eye (2.9%) required reoperation.
conclusionsA-stream implantation provided substantial short-term IOP reduction with low medication requirements and favorable qualified success through 6 months in NVG. Ripcord removal was frequently required and often performed early, supporting stepwise outflow titration as a practical postoperative strategy.
Indexed as
Identifiers
42025221What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.